Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Synthesis of peptides
Reexamination Certificate
2007-09-19
2009-10-27
Riley, Jezia (Department: 1637)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Synthesis of peptides
C424S450000, C424S085100, C205S254000, C514S001000, C536S084000
Reexamination Certificate
active
07608687
ABSTRACT:
A compound comprised of a hydrophilic polymer covalently yet reversibly linked to a amine-containing ligand through a dithiobenzyl linkage is described.
REFERENCES:
patent: 4021449 (1977-05-01), Fujimoto et al.
patent: 4179337 (1979-12-01), Davis et al.
patent: 4766106 (1988-08-01), Katre et al.
patent: 4902502 (1990-02-01), Nitecki et al.
patent: 4917888 (1990-04-01), Katre et al.
patent: 4935465 (1990-06-01), Garman
patent: 5059421 (1991-10-01), Loughrey et al.
patent: 5103556 (1992-04-01), Filip et al.
patent: 5169934 (1992-12-01), Clark et al.
patent: 5395619 (1995-03-01), Zalipsky et al.
patent: 5560923 (1996-10-01), Rahman et al.
patent: 5631018 (1997-05-01), Zalipsky et al.
patent: 5648090 (1997-07-01), Rahman et al.
patent: 5891468 (1999-04-01), Martin et al.
patent: 6180095 (2001-01-01), Greenwald et al.
patent: 6342244 (2002-01-01), Zalipsky
patent: 6365179 (2002-04-01), Zalipsky et al.
patent: 6605299 (2003-08-01), Zalipsky
patent: 6638500 (2003-10-01), El-Tayar et al.
patent: 6849270 (2005-02-01), Zalipsky
patent: 6984396 (2006-01-01), Zalipsky et al.
patent: 2004/0161455 (2004-08-01), Gabizon et al.
patent: 2004/0213759 (2004-10-01), Zalipsky et al.
patent: 0 317 956 (1989-05-01), None
patent: 0 317 957 (1989-05-01), None
patent: 0 510 197 (1992-10-01), None
patent: 0 898 968 (1999-03-01), None
patent: 2 254 336 (1975-07-01), None
patent: 62 178573 (1987-08-01), None
patent: 1113391 (1989-05-01), None
patent: WO 94/28780 (1994-12-01), None
patent: WO 96/10391 (1996-04-01), None
patent: WO 96/22303 (1996-07-01), None
patent: WO 97/36904 (1997-10-01), None
patent: WO 98/16201 (1998-04-01), None
patent: WO 99/29302 (1999-06-01), None
patent: WO 00/64483 (2000-11-01), None
patent: WO 00/64484 (2000-11-01), None
patent: WO 01/26629 (2001-04-01), None
patent: WO 02/26265 (2002-04-01), None
patent: WO 03/053409 (2003-07-01), None
patent: WO 2004/110497 (2004-12-01), None
Asai et al., “Antitumor activity of 5′-O-dipalmitoylphosphatidyl 2′-C-cyano-2′-deoxy-1- beta-D-arabino-pentofuranosylcytosine is enhanced by long-circulating liposomalization”,Biol. Pharm. Bull., 21(7):766-771 (1998).
Briddell et al.,Blood, 102(11):163b-164b Abstract #4364 (1999).
Brois, S.J., et al., “A new pathway to unsymmetrical disulfides. The thiol-induced fragmentation of sulfenyl thiocarbonates”,J. Amer. Chem. Soc., 92(26):7629-7631 (1970).
Database Dissertation Abstracts [Online] Proquest Info & Learning; Woghiren, Clement O. et al.: “Synthesis, Characterization and Conjugation of a Novel Protected Thiol-Polyethylene Glycol: A New Activated Polymer for Reversible Protein Modification (IL-2)” Dialog Accession No. 01367093; Dissertation Abstracts 55(03-B), 1994, p. 866.
Diaz et al., “Synthesis of disulfide-containing phospholipid analogs for the preparation of head group-specific lipid antigens: generation of phosphatidylserine antibodies”,Bioconjugate Chemistry, 9:250-254 (1998).
Dittmer, J.C., et al., “A simple, specific Spray for the detection of phospholipids on phospholipids on thin-layer chromatograms”,J. Lipid Res. 126-127 (1964).
Ellman, G.L., “Tissue sulfhydryl groups”,Archives of Biochemistry and Biophysics, 82:70-77 (1959).
Engman et al., “Thioredoxin reductase and cancer cell growth inhibition by organotellurium compounds that could be selectively incorporated into tumor cells.”,Bioorganic&Medical Chemistry, 11:5091-5100 (2003).
Gaber, M., et al., “Thermosensitive sterically stabilized liposomes: formulation and in vitro studies on mechanism of doxorubicin release by bovine serum and human plasma”,Pharmaceutical Res., 12(10):1407-1416, (1995).
Grassetti and Murray, “Determination of sulfhydryl groups with 2,2′- or 4,4′- dithiodipyridine”,Arch. Biochem. Biophys., 119(1):41-49 (1967).
Grice, R., et al., “Cytotoxic compounds. Part IV. Substituted benzyl halides”,J. Chem. Soc. 1947-1954 (1963).
Hirota, S., “Physicochemical specification of drug carrying liposomes for the quality control in the industrial production”,International J of Pharmaceutics162(1-2):185-194, (1998).
Johnson et al., “Amino-terminal dimerization of an erythropoietin mimetic peptide results in increased erythropoietic activity”,Chemistry and Biology, 4(12):939-950 (1997).
Johnsson, M., et al., “Optimization of Drug Loading Procedures and Characterization of Liposomal Formulations of Two Novel Agents Intended for Boron Neutron Capture Therapy (BNCT)”,J of Liposome Res9(1):53-79, (1999).
Kaneko, T., et al., “New hydrazone derivatives of adriamycin and their immunoconjugates—a correlation between acid stability and cytotoxicity”,Bioconjugate Chem. 2(3):133-141 (1991).
Kirpotin, D., et al., “Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly(ethylene glycol)”,FEBS Letters, 388:115-118, (1996).
Kratz et al., “Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound”,J. Med. Chemistry, 45(12):5523-5533 (2002).
Lash, L.H., et al., “Distribution of oxidized and reduced forms of glutathione and cysteine in rat plasma”,Arch. Biochem. Biophys. 240(2):583-592 (1985).
Malik et al., “A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia”,Experimental Hematology, 28(7, Suppl. 1):106, Abstract No. 237 (2000).
Thorpe et al., “New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo”,Cancer Res., 47(12):5924-5931 (1987).
Vaage, J., et al., “Therapy of a xenografted human colonic carcinoma using cisplatin or doxorubicin encapsulated in long-circulating pegylated stealth liposomes”,International Journal of Cancer, 80(1):134-137 (1999).
Vaage, J., et al., “Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes”,Cancer, 72(12):3671-3675, (1993).
Vaage, J., et al., “Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts”,Cancer73(5):1478-1484, (1994).
Vaage, J., et al., “Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes”,International J of Cancer, 51(6):942-948, (1992).
Worrell et al., “Effect of linkage variation on pharmacokinetics of ricin A chain-antibody conjugates in normal rats”,Anticancer Drug Design, 1(12):179-188 (1986).
Zalipsky, “New detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine”,Bioconj Chem., 10(5):703-707, (1999).
Zalipsky, et al., “Synthesis of an end-group functionalized polyethylene glycol-lipid conjugate for preparation of polymer-grafted liposomes”,Bioconj. Chem., 4(4):296-299 (1993).
Zalipsky, et al., “Evaluation of a new reagent for covalent attachment of polyethylene glycol to proteins”,Biotechnol. Appl. Biochem., 100-114 (1992).
Zalipsky, et al., “Attachment of drugs to polyethylene glycols”,Eur. Polymer. J., 19(12):1177-1183 (1983).
Zalipsky, S., et al., 28thInternational Symposium on Controlled Release of Bioactive Materials and 4thConsumer & Diversified Products Conference, San Diego, CA, Publisher: Controlled Release Society 1:437-438, (2001).
Boeckler, C. et al., “Immunogenicity of new heterobifunctional cross-linking reagents used in the conjugation of synthetic peptides to liposomes”,Journal of Immunolog
Alza Corporation
Riley Jezia
LandOfFree
Releasable linkage and compositions containing same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Releasable linkage and compositions containing same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Releasable linkage and compositions containing same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4138001